BR0302584A - Combinação de brimonidina e timolol para uso oftálmico tópico - Google Patents

Combinação de brimonidina e timolol para uso oftálmico tópico

Info

Publication number
BR0302584A
BR0302584A BR0302584-5A BR0302584A BR0302584A BR 0302584 A BR0302584 A BR 0302584A BR 0302584 A BR0302584 A BR 0302584A BR 0302584 A BR0302584 A BR 0302584A
Authority
BR
Brazil
Prior art keywords
brimonidine
topical ophthalmic
timolol
ophthalmic use
combination
Prior art date
Application number
BR0302584-5A
Other languages
English (en)
Inventor
Chin-Ming Chang
Gary J Beck
Cynthia C Pratt
Amy L Batoosingh
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29215107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0302584(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR0302584A publication Critical patent/BR0302584A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F21—LIGHTING
    • F21V—FUNCTIONAL FEATURES OR DETAILS OF LIGHTING DEVICES OR SYSTEMS THEREOF; STRUCTURAL COMBINATIONS OF LIGHTING DEVICES WITH OTHER ARTICLES, NOT OTHERWISE PROVIDED FOR
    • F21V23/00—Arrangement of electric circuit elements in or on lighting devices
    • F21V23/001—Arrangement of electric circuit elements in or on lighting devices the elements being electrical wires or cables
    • F21V23/002—Arrangements of cables or conductors inside a lighting device, e.g. means for guiding along parts of the housing or in a pivoting arm
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F21—LIGHTING
    • F21V—FUNCTIONAL FEATURES OR DETAILS OF LIGHTING DEVICES OR SYSTEMS THEREOF; STRUCTURAL COMBINATIONS OF LIGHTING DEVICES WITH OTHER ARTICLES, NOT OTHERWISE PROVIDED FOR
    • F21V23/00—Arrangement of electric circuit elements in or on lighting devices
    • F21V23/003—Arrangement of electric circuit elements in or on lighting devices the elements being electronics drivers or controllers for operating the light source, e.g. for a LED array
    • F21V23/004—Arrangement of electric circuit elements in or on lighting devices the elements being electronics drivers or controllers for operating the light source, e.g. for a LED array arranged on a substrate, e.g. a printed circuit board
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F21—LIGHTING
    • F21V—FUNCTIONAL FEATURES OR DETAILS OF LIGHTING DEVICES OR SYSTEMS THEREOF; STRUCTURAL COMBINATIONS OF LIGHTING DEVICES WITH OTHER ARTICLES, NOT OTHERWISE PROVIDED FOR
    • F21V23/00—Arrangement of electric circuit elements in or on lighting devices
    • F21V23/02—Arrangement of electric circuit elements in or on lighting devices the elements being transformers, impedances or power supply units, e.g. a transformer with a rectifier
    • F21V23/023—Power supplies in a casing
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/0001—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings specially adapted for lighting devices or systems
    • G02B6/0011—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings specially adapted for lighting devices or systems the light guides being planar or of plate-like form
    • G02B6/0066—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings specially adapted for lighting devices or systems the light guides being planar or of plate-like form characterised by the light source being coupled to the light guide
    • G02B6/0073—Light emitting diode [LED]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Power Engineering (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMBINAçãO DE BRIMONIDINA E TIMOLOL PARA USO OFTáLMICO TóPICO". A presente invenção refere-se a composições farmacêuticas compreendendo brimonidina e timolol para distribuição oftálmica tópica e um método de tratamento compreendendo administrar a referida composição quando indicada para glaucoma e patologias associadas tal como pressão intra-ocular alta nos olhos de seres humanos.
BR0302584-5A 2002-04-19 2003-04-09 Combinação de brimonidina e timolol para uso oftálmico tópico BR0302584A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/126,790 US7030149B2 (en) 2002-04-19 2002-04-19 Combination of brimonidine timolol for topical ophthalmic use
PCT/US2003/010885 WO2003088973A1 (en) 2002-04-19 2003-04-09 Combination of brimonidine and timolol for topical ophthalmic use

Publications (1)

Publication Number Publication Date
BR0302584A true BR0302584A (pt) 2004-03-09

Family

ID=29215107

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0302584-5A BR0302584A (pt) 2002-04-19 2003-04-09 Combinação de brimonidina e timolol para uso oftálmico tópico

Country Status (17)

Country Link
US (16) US7030149B2 (pt)
EP (2) EP2241319A1 (pt)
JP (1) JP2005523316A (pt)
KR (1) KR100723189B1 (pt)
CN (2) CN101664414A (pt)
BR (1) BR0302584A (pt)
CA (1) CA2440764C (pt)
CY (1) CY1114048T1 (pt)
DK (1) DK1496912T3 (pt)
ES (1) ES2399045T3 (pt)
MX (2) MXPA03008401A (pt)
NO (1) NO326579B1 (pt)
NZ (1) NZ528945A (pt)
PT (1) PT1496912E (pt)
SI (1) SI1496912T1 (pt)
TW (1) TWI351959B (pt)
WO (1) WO2003088973A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
CN100413503C (zh) * 2005-01-07 2008-08-27 冷文 一种复方眼药组合物
US7534795B2 (en) 2005-10-25 2009-05-19 Allergan, Inc. Compounds and their use related to compositions for treating disease
US20070238732A1 (en) * 2006-04-10 2007-10-11 Allergan, Inc. Brimonidine and timolol compositions
US20080051406A1 (en) * 2006-08-25 2008-02-28 Richard Graham Brimonidine and timolol compositions
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
MX2007010025A (es) * 2007-08-17 2009-02-25 Arturo Jimenez Bayardo Composición farmacéutica para tratamiento de hipertensión ocular.
MX2007011165A (es) * 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
ES2518418T3 (es) 2008-08-01 2014-11-05 Eye Therapies Llc Composiciones de vasoconstricción y métodos de uso
JP5218167B2 (ja) 2009-03-11 2013-06-26 日立電線株式会社 コネクタ
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
US8317973B2 (en) 2009-11-11 2012-11-27 Kemira Chemical, Inc. Polyester surfactants for deinking
WO2011075621A1 (en) * 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions and methods for ophthalmic delivery of nasal decongestants
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
CN102695498A (zh) * 2009-12-22 2012-09-26 阿勒根公司 用于降低眼内压的组合物和方法
WO2012016000A2 (en) 2010-07-29 2012-02-02 Allergan, Inc. Preservative free brimonidine and timolol solutions
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
EP2790673B1 (en) * 2011-12-16 2017-07-05 Allergan, Inc. Ophthalmic compositions comprising polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers (soluplus)
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
CA2977825A1 (en) * 2015-03-19 2016-09-22 Allergan, Inc. Fixed dose combination of brimonidine and timolol
AU2017310520A1 (en) 2016-08-12 2019-03-21 Silk Technologies, Ltd. Silk-derived protein for treating inflammation
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
MA47418A (fr) * 2017-02-01 2021-06-02 Takeda Pharmaceuticals Co Composés et compositions pour le traitement de troubles ophtalmiques
US20200108064A1 (en) * 2017-06-08 2020-04-09 Eye Therapies, Llc Low-dose brimonidine combinations and uses thereof
AU2018279074B2 (en) * 2017-06-08 2023-12-14 Eye Therapies, Llc Low-dose brimonidine combinations and uses thereof
MX2020003560A (es) * 2017-09-25 2020-08-03 Univ Florida Eliminacion de conservantes de gotas oftalmicas que contienen farmacos hidrofilos.
US20190134051A1 (en) * 2017-11-06 2019-05-09 Rheostasis, Llc Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma
IL276888B2 (en) * 2018-03-28 2024-12-01 Novaliq Gmbh Pharmaceutical composition comprising timolol
US11871308B2 (en) * 2019-07-29 2024-01-09 TapText llc System and method for link-initiated dynamic-mode communications
WO2021141672A2 (en) 2019-11-15 2021-07-15 Silk Technologies, Ltd. Stable formulations of silk-derived protein
CN115397374A (zh) 2019-12-19 2022-11-25 特清公司 从滴眼剂中去除防腐剂
CN120617269A (zh) * 2025-06-16 2025-09-12 鲁南贝特制药有限公司 一种溴莫尼定噻吗洛尔滴眼液及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4195085A (en) * 1975-09-26 1980-03-25 Merck & Co., Inc. Compositions and methods for treating glaucoma by the topical administration of t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy-2-phopanol hydrogen maleate
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
CA1325382C (en) * 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
CA1334168C (en) 1988-04-26 1995-01-31 Louis M. De Santis Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers
IL92351A (en) * 1988-11-29 1994-02-27 Allergan Inc Irvine Aqueous opthalmic solutions containing stabilized chlorine dioxide and an inorganic salt
US5021410A (en) * 1989-05-22 1991-06-04 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) * 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
DE4201079C3 (de) 1992-01-17 1997-09-11 Gramer Eugen Kombinationspräparate zur Augeninnendrucksenkung
US5290781A (en) * 1993-01-05 1994-03-01 Iolab Corporation Ketaneserinol as an agent to reduce intraocular pressure
TW354762B (en) * 1993-02-23 1999-03-21 Otsuka Pharma Co Ltd Agent for prophylaxis or treatment of cataract
DK0735877T3 (da) 1993-12-17 2000-11-06 Procter & Gamble 6-(2-imidazolinylamino)quinoxalinforbindelser, der er egnede som alfa-2-adrenoceptoragonister.
US5440505A (en) * 1994-01-21 1995-08-08 Intel Corporation Method and circuitry for storing discrete amounts of charge in a single memory element
SE9401109D0 (sv) * 1994-03-31 1994-03-31 Leiras Oy Opthalmic composition II
US5564596A (en) * 1994-05-05 1996-10-15 Allergan, Inc. Multiple fluid dispensing device for low surface tension formulations
US6294563B1 (en) * 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5856329A (en) 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
CA2237898A1 (en) * 1995-11-17 1997-05-29 Louis Desantis Jr. Combination therapy for treating glaucoma
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US6159458A (en) * 1997-11-04 2000-12-12 Insite Vision Sustained release ophthalmic compositions containing water soluble medicaments
US6174524B1 (en) * 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
PT1069913E (pt) * 1998-04-07 2003-11-28 Alcon Mfg Ltd Composicoes oftalmicas gelificantes contendo goma xantana
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
US6740664B2 (en) * 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
US6146622A (en) * 1998-10-27 2000-11-14 Alcon Laboratories, Inc. Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
US6242442B1 (en) * 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
US6410045B1 (en) * 1999-02-22 2002-06-25 Clyde Lewis Schultz Drug delivery system for antiglaucomatous medication
AU5754701A (en) * 2000-07-13 2002-01-30 Pharmacia Corp Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
JP4927298B2 (ja) * 2000-07-14 2012-05-09 アラーガン、インコーポレイテッド α−２−アドレナリンアゴニスト成分を含有する組成物
AU2001273268B2 (en) * 2000-07-14 2005-08-25 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
TWI292914B (pt) * 2002-01-17 2008-01-21 Macronix Int Co Ltd
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US7642258B2 (en) * 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
KR100521364B1 (ko) * 2002-11-18 2005-10-12 삼성전자주식회사 플레쉬 메모리 셀들의 프로그램 오판을 방지하고 균일한문턱 전압 산포를 가질 수 있는 플레쉬 메모리 장치 및 그프로그램 검증 방법

Also Published As

Publication number Publication date
TWI351959B (en) 2011-11-11
US20150087647A1 (en) 2015-03-26
MX368377B (es) 2019-09-30
US9907802B1 (en) 2018-03-06
US9474751B1 (en) 2016-10-25
US8748425B2 (en) 2014-06-10
US20030199507A1 (en) 2003-10-23
CY1114048T1 (el) 2016-07-27
EP1496912A1 (en) 2005-01-19
US20180064720A1 (en) 2018-03-08
CN100558364C (zh) 2009-11-11
CA2440764C (en) 2005-10-25
CN101664414A (zh) 2010-03-10
US8354409B2 (en) 2013-01-15
US20210405280A1 (en) 2021-12-30
EP1496912B9 (en) 2015-06-17
US9907801B1 (en) 2018-03-06
US20130116255A1 (en) 2013-05-09
US20170157138A1 (en) 2017-06-08
JP2005523316A (ja) 2005-08-04
HK1067549A1 (zh) 2005-06-03
TW200402296A (en) 2004-02-16
KR100723189B1 (ko) 2007-05-29
CN1516588A (zh) 2004-07-28
KR20040100844A (ko) 2004-12-02
US20080132512A1 (en) 2008-06-05
US20040102445A1 (en) 2004-05-27
AU2003228480A1 (en) 2003-11-03
US20130324534A1 (en) 2013-12-05
US20180042932A1 (en) 2018-02-15
US7030149B2 (en) 2006-04-18
NO20044450L (no) 2004-11-09
NZ528945A (en) 2006-04-28
US20200129520A1 (en) 2020-04-30
US20130196995A1 (en) 2013-08-01
US20160303119A1 (en) 2016-10-20
WO2003088973A1 (en) 2003-10-30
AU2003228480B2 (en) 2006-07-27
US7320976B2 (en) 2008-01-22
US7323463B2 (en) 2008-01-29
ES2399045T3 (es) 2013-03-25
PT1496912E (pt) 2013-02-13
EP2241319A1 (en) 2010-10-20
US9770453B2 (en) 2017-09-26
US20030199509A1 (en) 2003-10-23
SI1496912T1 (sl) 2013-03-29
US20120184551A1 (en) 2012-07-19
MXPA03008401A (es) 2004-03-16
NO326579B1 (no) 2009-01-12
CA2440764A1 (en) 2003-10-19
US8133890B2 (en) 2012-03-13
EP1496912B1 (en) 2013-01-09
DK1496912T3 (da) 2013-04-02
US20180064721A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
CA2440764A1 (en) Combination of brimonidine and timolol for topical ophthalmic use
NZ588938A (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
BRPI0506983A (pt) composições para terapia localizada dos olhos, compreendendo preferencialmente acetonida de triancinolona e ácido hialurÈnico
WO2008011836A3 (es) Soluciones oftálmicas
BR9808282A (pt) Liberação controlada de produtos farmacêuticos na câmara anterior do olho
MX2010003774A (es) Formulaciones oftalmicas acuosas.
BRPI0414699A (pt) formulações de acetato de anecortave e acetonida de triancinolona para injeção
EP2598119B1 (en) Preservative free brimonidine and timolol solutions
NZ602445A (en) Ketorolac tromethamine compositions for treating or preventing ocular pain
WO2006082588A3 (en) Method and device for ophthalmic administration of active pharmaceutical ingredients
AU2011274245B2 (en) Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease
JP2005523316A5 (pt)
BR0210013A (pt) Gel oftálmico de pirenzepina
WO2002009702A3 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
WO2004012762A3 (en) Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
MX2021016055A (es) Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis.
CA2582316A1 (en) Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
AR032138A1 (es) Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma
NZ602479A (en) Pharmaceutical composition for the treatment of dry eye and/or corneal and conjunctival lesion
RU99121654A (ru) Средства для предотвращения или лечения болезней, связанных с чрезмерной пролиферацией эпителиальных пигментных клеток сетчатки
WO2005115432A3 (en) Treatment of ocular diseases and disorders using lantibiotic compositions
KR20190071674A (ko) 안과용 제제 및 안과용 약
AU2001267864A1 (en) Remedial agent for optic nerve disease and the like
ECSP034742A (es) Combinacion de brimonidina y timolol para uso oftalmologico topico
AR038363A1 (es) Combinacion de brimonidina y timolol para uso oftalmico topico

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: REFERENTE A RPI NO1896 DE 08/05/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8 E 13 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B15W Others matters related to applications: legal action concerning application
B15N Others concerning applications: notification of judicial decision